What is the likely diagnosis and recommended diagnostic and therapeutic approach for a unilateral purpuric rash on the lower extremity in a patient with polymyalgia rheumatica and Waldenström macroglobulinemia?

Likely Diagnosis: Cutaneous Macroglobulinosis or Hypergammaglobulinemic Purpura

The unilateral purple discoloration/purpuric rash in this patient with Waldenström macroglobulinemia most likely represents cutaneous macroglobulinosis from IgM deposition in dermal vessels, though hypergammaglobulinemic purpura of Waldenström (HGPW) and cryoglobulinemia-related vasculopathy are important differential considerations.

Diagnostic Approach

Immediate Clinical Assessment

Examine for specific features that distinguish between etiologies:

• Palpability of purpura: Palpable lesions suggest leukocytoclastic vasculitis 1
• Temperature sensitivity: Cold-induced symptoms point toward cryoglobulinemia 2
• Distribution pattern: Serpiginous patterns are characteristic of cutaneous macroglobulinosis 1
• Associated symptoms: Ulceration, nodules, or plaques suggest direct IgM deposition 3

Essential Laboratory Workup

Order these specific tests immediately:

• Serum IgM quantification (nephelometry preferred for accuracy) 4
• Serum viscosity if IgM >4000 mg/dL or any hyperviscosity symptoms 4
• Cryoglobulins with cold agglutinins 4
• Rheumatoid factor (IgG and IgA) and polyclonal hypergammaglobulinemia assessment 5
• Complete blood count to assess for cytopenias 4

Skin Biopsy with Specific Staining

Perform a punch biopsy of the purpuric lesion with direct immunofluorescence and immunohistochemistry for IgM deposition 1. This is the definitive diagnostic test. The biopsy will reveal:

• Cutaneous macroglobulinosis: IgM deposits in vessel walls and lumens with vasculopathy/vasculitis 1
• HGPW: Leukocytoclastic vasculitis without monoclonal IgM deposits 5
• Cryoglobulinemic vasculitis: Vessel occlusion with cryoprecipitates

Therapeutic Approach

If Hyperviscosity is Present

Initiate plasmapheresis immediately alongside systemic WM therapy 4. This is a level IV, grade A recommendation for urgent IgM reduction.

Systemic WM Treatment Indications

The purpuric rash itself constitutes symptomatic cryoglobulinemia or IgM-related complication, which is an indication to initiate WM-directed therapy 4, 6.

First-line treatment options based on clinical presentation:

For patients with neuropathy concerns (given polymyalgia rheumatica overlap):

• Dexamethasone/rituximab/cyclophosphamide (DRC) 4
• Bendamustine/rituximab (BR) 4
• Avoid proteasome inhibitors due to neurotoxicity risk 4

For patients without neuropathy:

• Bortezomib/dexamethasone/rituximab (BDR) or bortezomib/rituximab (VR) 4
• Zanubrutinib (covalent BTK inhibitor) 7
• Bendamustine/rituximab 4

Critical Caveat About Rituximab Monotherapy

Do not use rituximab monotherapy if serum IgM is very high 6. Rituximab can paradoxically cause IgM flare before reduction, worsening hyperviscosity and purpura. If IgM >4000 mg/dL, consider preemptive plasmapheresis 4.

Symptomatic Management

For symptomatic cryoglobulinemia with purpura:

• Rituximab combined with corticosteroids 6
• Avoid cold exposure
• Elevate affected limb
• Consider colchicine for HGPW if conservative measures fail 5

Polymyalgia Rheumatica Consideration

The polymyalgia rheumatica diagnosis requires careful evaluation here. PMR typically presents with bilateral proximal muscle pain and stiffness 8. However, unilateral purpura is not a feature of PMR. Consider:

• Is this true PMR or WM-related symptoms?
• WM can cause constitutional symptoms mimicking PMR
• If confirmed PMR on corticosteroids, this may actually help the purpuric manifestations
• Ensure purpura is not from microscopic polyangiitis (ANCA-associated vasculitis), which can present similarly 9

Key Pitfalls to Avoid

1. Do not delay skin biopsy - clinical appearance alone cannot distinguish between cutaneous macroglobulinosis, HGPW, and cryoglobulinemic vasculitis
2. Do not assume bilateral disease is required - cutaneous macroglobulinosis can present unilaterally 1
3. Do not start rituximab monotherapy without checking IgM levels and viscosity - risk of IgM flare 6
4. Do not attribute all symptoms to PMR - WM can cause similar constitutional symptoms and the purpura suggests WM-related pathology
5. Screen for hepatitis B before any WM therapy - reactivation risk with immunosuppression 10